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nicotine patches for smoking cessation
Abstract

Introduction: Nicotine addiction has become one of the largest international health problems, increasing the
risk of cardiovascular disease, cancers, and respiratory diseases. There are several treatments available for
smoking cessation with the most common transdermal nicotine replacement and anti-depressants. However
current treatments are only mildly efficacious and have side effects which lead to a decrease in their
effectiveness. Additional treatments for smoking cessation with lower side effects are required. Methods: We
examined the efficacy of Remotiv® (Hypericum perforatum Special Extract - ZE117) compared to Nicabate®
CQ Nicotine Replacement Therapy (NRT) and combination ZE117/NRT for smoking cessation over a
treatment time of 10 weeks. Given the different pharmacological profiles of Ze117 and NRT it was expected
that a combination treatment would be most efficacious for smoking cessation than the other two treatments
alone. Sixty smokers aged between 18 and 60 years were enrolled in the study. Smoking status was assessed
using CO levels measured by the Bedfont Smokerlyzer (primary outcome measure). Secondary outcome
measures of anxiety, DSMIV nicotine dependence and Fagerström craving and symptoms were also recorded.
Results: A significant main effect of reduction in the number of smokers over the course of the study was
observed although there were no significant differences between any of the treatment groups on this variable
after 14 weeks. Conclusions: These results indicate that the three treatment options are equally efficacious for
smoking cessation. Interestingly the Ze117 treatment significantly reduced the amount of craving over the
treatment duration of the study compared to the other two treatments indicating a possible mechanism by
which Ze117 may assist in smoking cessation.
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Abstract
Introduction: Nicotine addiction has become one of the largest international health problems, increasing
the risk of cardiovascular disease, cancers, and respiratory diseases. There are several treatments available for
smoking cessation with the most common transdermal nicotine replacement and anti-depressants. However current
treatments are only mildly efficacious and have side effects which lead to a decrease in their effectiveness. Additional
treatments for smoking cessation with lower side effects are required.
Methods: We examined the efficacy of Remotiv® (Hypericum perforatum Special Extract - ZE117) compared
to Nicabate® CQ Nicotine Replacement Therapy (NRT) and combination ZE117/NRT for smoking cessation over a
treatment time of 10 weeks. Given the different pharmacological profiles of Ze117 and NRT it was expected that a
combination treatment would be most efficacious for smoking cessation than the other two treatments alone. Sixty
smokers aged between 18 and 60 years were enrolled in the study. Smoking status was assessed using CO levels
measured by the Bedfont Smokerlyzer (primary outcome measure). Secondary outcome measures of anxiety, DSMIV nicotine dependence and Fagerström craving and symptoms were also recorded.
Results: A significant main effect of reduction in the number of smokers over the course of the study was
observed although there were no significant differences between any of the treatment groups on this variable after
14 weeks.
Conclusions: These results indicate that the three treatment options are equally efficacious for smoking
cessation. Interestingly the Ze117 treatment significantly reduced the amount of craving over the treatment duration
of the study compared to the other two treatments indicating a possible mechanism by which Ze117 may assist in
smoking cessation.
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Introduction
Nicotine addiction has become one of the largest international
health problems, increasing the risk of life threatening diseases. It is
estimated that smoking causes an alarming 22% of cardiovascular
disease, 30% of all cancers, 70-90% of lung cancers and 56-80% of
respiratory diseases [1]. With 21% of the Australian adult population
classed as regular smokers, cigarette smoking has been reported to
be responsible for 19,000 Australian deaths each year [2]. Smokingrelated illnesses contribute significantly to healthcare costs and pose
a considerable burden on the healthcare system and are estimated to
cost the Australian community $21 billion dollars annually [3]. Even
for those who choose to quit smoking, cessation may be difficult and
is often unsuccessful. Community quit rates for smokers attempting to
quit without pharmacological treatment or supportive counselling have
been reported as 17% [4], which should be seen as unacceptably low
given the negative health consequences of smoking.
Drugs of addiction exert influence over the brain reward pathway
[5]. It is thought that dopaminergic stimulation of the nucleus
accumbens reinforces use of the drug [6]. Addictive drugs may either
directly influence the action of the neurotransmitter dopamine, or alter
the activity of other neurotransmitters that exert a modulatory influence
over the mesolimbic dopaminergic pathway [5]. Gamma aminobutyric
acid (GABA), opioid, serotonergic, cholinergic and noradrenergic
neurotransmitter pathways have all been shown to interact at various
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points along the mesolimbic dopaminergic pathway and to modulate
its activity [7].
As one of the most addictive drugs of abuse, nicotine exerts direct
influence on nicotinic acetylcholine (ACh) receptors located on the
cell bodies of dopamine neurons within the ventral tegmental area
(VTA) [8]. Activation of these nicotinic ACh receptors increases the
action of dopamine neurons, resulting in stimulation of the nucleus
accumbens [9,10]. Additionally, nicotinic receptors located on other
neurotransmitter inputs to the VTA may further increase dopamine
release by removing the inhibitory influence of other neurotransmitters
(i.e. decrease GABA and increase Glutamate [7,8].
The biology of nicotine addiction has also been found to be linked
to changes in serotonergic transmission associated with chronic use
[11]. Acute smoking has been found to increase serotonin release,
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while chronic smoking decreasing the concentration and synthesis of
brain serotonin [12]. An increase in serotonin transporter density in
the prefrontal cortex has also been found to be associated with chronic
nicotine administration [13,14] . During nicotine withdrawal there
appears to be an increased sensitivity of serotonin neurons in the dorsal
raphe nucleus [15].
Current pharmacological methods for treating smoking addiction
in Australia that are approved by the government regulator include
Nicotine Replacement Therapy (NRT) and Bupropion [16]. In the
USA, the Food and Drug Administration (FDA) have approved a
number of Nicotine Replacement Therapies including nicotine patches,
gum, lozenges, sprays and inhalers [17]. There have also been two
other pharmacological treatments approved by the FDA: Varenicline
and Buproprion [18]. Randomised trials have found Buproprion to be
effective in assisting cessation of smoking. Hurt et al., [19] reported
the seven week quit rate for Bupropion to be significantly greater
than the placebo quit rate of 19%. While Bupropion has been shown
to be effective in the management of smoking cessation, there are
significant adverse effects associated with its use including seizures,
insomnia, dizziness, headache and skin reactions [16]. Although not
substantiated by research, there have been anecdotal reports of sudden
death associated with Bupropion Two randomised controlled trials
have reported that 12 weeks treatment with Varenicline to be more
effective than Bupropion in the maintenance of continuous abstinence
rates during weeks 9 to 24 after quit date [20-22]. Quit rates associated
with Varenicline were reported to be 44% and 43.9%, while quit rates
associated with Bupropion were 29.5% and 29.8%, and quit rates
for placebo were 14% and 17.7% [20-22]. A number of adverse side
effects associated with Varenicline use were reported in these studies,
including nausea, headache, insomnia and abnormal dreams [20-22].
Discontinuation of treatment due to adverse events occurred in 8.6%
and 10.5% of recipients in the Varenicline group and 15.2% and 12.6%
in the Bupropion group compared to 9.0% and 7.3% of participants in
the placebo group [20-22]. Gonzales et al., [20] reported two serious
adverse events attributed to the study treatment: an episode of atrial
fibrillation was attributed to Varenicline and a grand mal seizure
attributed to Buproprion. Jorenby et al., [21] also reported serious
adverse effects including vertigo, hypertension and chest pain in a
participant receiving Varenicline and angioedema in a Bupropion
recipient.

Nicotine Replacement Therapy (NRT)
NRT assists in smoking cessation by providing a constant level
of nicotine to prevent withdrawal effects [23] and has been reported
to be safe and effective in relieving withdrawal symptoms associated
with smoking cessation 24,25]. Delivery modes for NRT include
Transdermal nicotine (TN), gum, sublingual tablets and oral inhalers
[16]. In a meta-analysis of randomised trials, Silagy et al., [26] found
no significant difference in cessation rates for different delivery modes,
tapering of dose versus abrupt withdrawal and 12 week compared to 28
week treatment [26]. Slowed delivery (i.e. sustained release) of nicotine
using TN is considered the preferred form of NRT, as it has the lowest
potential for addiction [27] TN is also considered to be the easiest form
to use and has the lowest level of adverse effects [28,29].
Hays et al., [29] conducted a double-blind placebo controlled
trial which compared the efficacy of six week treatment of daily 22mg
nicotine patches (TN) compared to placebo. They also included an open
label arm to compare the efficacy of the same therapy with participants
purchasing their own patches. Smoking cessation rates were greater
for TN (16.8%; 8.7%) in comparison to placebo (9.6%; 4.3%) in
Altern Integ Med
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the controlled trial at weeks 6 and 24. There was a slight increase in
cessation rates in the open label arm of the trial (19.0%; 10.8%) at weeks
6 and 24 [29].
Adverse effects of NRT may be associated with delivery mode or
the effects of the nicotine itself. Adverse effects that are specific to the
mode of delivery include: nasal irritation and runny nose for nasal
spray; coughing, throat irritation and oral burning for inhalation; skin
rash for TN; jaw pain and hiccups from chewing the gum; dry lips,
mouth ulcers and sore throat from sublingual tablets [30]. Nicotine
related adverse effects associated with all modes of delivery include,
dry mouth, nausea, headache and palpitations [16]. These side effects
greatly contribute to the relatively low effect size of these delivery
systems in smoking cessation trials.
Cochrane reviews have indicated that the effectiveness of all three
treatments are relatively poor with a high degree of relapse at 6 months
[17,31,32]. Clearly alternative treatments with lower side effects are
urgently required for nicotine addiction. For some individuals a new
treatment may be important after failing current treatments and
therefore additional choice may be important. Additionally a new
treatment may also be important if it is more cost effective than current
treatments.

Hypericum perforatum and smoking cessation
The pharmacological properties of Hypericum perforatum (HP)
suggest a potential role in reducing addiction to nicotine. HP is the only
antidepressant capable of inhibiting the reuptake of the monoamines:
serotonin, noradrenaline and dopamine with similar potencies [33,34].
HP has previously been found to normalize dopaminergic as well
as noradrenergic transmission in the medial PFC [35,36]. Recently
Ruedeberg et al., [37] have argued for the use of HP in smoking
cessation based on dopamine re-uptake in rat striatal cortex after
HP administration. HP also inhibits the reuptake of amino acids and
neurotransmitters GABA and glutamate [33,34] suggesting that HP
both directly and indirectly influences the dopamine reward pathways.
Preclinical research has provided evidence to suggest that chronic
HP supplementation also enhances serotoninergic transmission in the
PFC [38] and may be of benefit in counteracting the deleterious neural
effects of chronic stress [39]. These findings are particularly relevant to
individuals undergoing nicotine withdrawal, as smoking abstinence has
been found to be associated with elevations in stress hormones [40].
With proven efficacy as an antidepressant for mild to moderate clinical
depression [41,42], HP may also assist in cessation of smoking via
reduction in depressive symptoms associated with nicotine withdrawal.
Although conventional anti-depressants have been shown to reduce
the urges associated with nicotine withdrawal they have not been
shown to be efficacious in abstinence [23]. Dopaminergic acting drugs
however have been shown to decrease both the symptoms of nicotine
withdrawal and abstinence rates but show significant side-effects. As
Parsons et al., [43] have argued, because HP acts uniquely on both of
these neurotransmitter systems it is important to directly test whether
HP directly improves smoking abstinence. Certainly the side-effect
profile of HP is significantly better than other treatments for smoking
cessation. HP does not appear to have the anticholinergic effects
(delirium, sedation, cognitive impairment) of other antidepressants
[44] and the adverse effect profile of HP is extremely good compared to
other antidepressants [41,42].
The potential benefit of HP on smoking cessation has been
investigated in animal studies as well as preliminary clinical trials in
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humans. Barnes et al., [45] conducted an open, uncontrolled pilot study
to examine the effects of HP (LI-160) on smoking cessation. Twentyeight participants were administered 300mgor 600mg HP (equivalent
to 900 mcg or 1800 mcg hypericin) daily, with treatment commencing
one week prior to the quit date and continuing for 12 weeks after quit
date. The abstinence rates at 3 months and 12 months after the quit date
were 18% and 0% respectively for the combined HP treatment groups.
Barnes et al., [45] concluded that the results did not provide convincing
evidence for the efficacy of HP as an aid in smoking cessation. However
there were a number of problems with this trial including the very
small sample size, and a run-in period for HP that was too brief for
the treatment to be effective. As with most antidepressants, four to six
weeks of treatment is typically required to achieve therapeutic benefit
[46].
Lawvere et al., [47] also examined the efficacy of a daily dose of
900mg HP (equivalent to hypericin 2700 mcg) on cessation rates of 24
smokers in an open-label trial. Treatment commenced a week before
quit date and continued a further 12 weeks after quit date. Thirty-five
percent of participants were found to be smoke free at 12 weeks after the
quit date. Anxiety was also found to be significantly reduced from the
third to the twelfth week after the quit date, and a decrease in depression
scores and nicotine withdrawal symptoms was evident during the 12
week course of the study [47]. Lawvere et al., [47] concluded that HP
may prove to be a useful adjunctive therapy for smoking cessation.
In a more recent placebo controlled clinical trial Parsons et al.,
[43] examined the efficacy of 900mg HP daily (equivalent to hypericin
1080-2520 mcg) versus placebo for 16 weeks. In a factorial design
participants were also allocated chromium or placebo. There were
no significant differences between the SJW and the placebo group
at either 4 or 16 weeks indicating that the HP used in this study was
not effective in smoking abstinence. Surprisingly there was also no
significant difference in any of the mood related variables or urges to
smoke between the HP and placebo groups indicating that the HP in
this trial did not effectively increase serotononergic or dopaminergic
activity which would have decreased nicotine cravings and negative
moods. In a similar trial using another different HP extract, Sood et al.,
[48] administered 900 mg HP/day versus 1800 mg HP/day (equivalent
to hypericin 2700 mcg and hypericin 5400 mcg) for 12 weeks in 118
participants. Sood et al., [48] reported that there were no significant
differences in abstinence rates between either of the HP groups or
placebo at both12 or 24 weeks post-treatment.
In consideration of the strong preclinical evidence of central
dopaminergic effects associated with HP [35,36], the mixed results
of these human trials are hard to reconcile. One possible explanation
for the different findings for each of these trials may be attributed to
use of different HP extracts, with differences in quality across different
manufacturers. Unlike pharmaceuticals in which an active compound
is concentrated and reliably reproduced from batch to batch, a
nutraceutical like HP may significantly differ for a number of factors
including climatic conditions during growth, geographical location,
extraction technique, as well as handling and transportation techniques.

medications [53,54]. Ze 117 has been used in an estimated 6 million
patients in the last 10 years, with an extremely low incidence of reported
side effects in trials and in clinical use (Periodic Safety Update Report,
Ze 117 March 2004).
A pilot study from our laboratory conducted in 2006 examined
the effects of Ze117 HP extract (Ze117; 500mcg Hypericin 2/d) in the
management of smoking cessation compared to a transdermal nicotine
patch (Nicabate CQ; step down regime commencing at 24 mg/day) [55].
Forty Participants aged between 18 and 60 years who had smoked for
at least 5 years and were wishing to quit smoking were enrolled in the
study. The study was conducted over a 14 and 10 week administration
period for the HP and NRT groups, respectively. The results of the
study revealed that participants in both the HP (n=17) and NRT (n=12)
groups decreased the number of cigarettes smoked per day over the
12 week treatment period. Quit rates for the HP and TN groups were
not statistically different indicating that there were equivalent numbers
of smokers from both the HP and TN groups who were able to quit
smoking.

The current study
The current study extended on the methodology of the initial
pilot study from our laboratory, examining the efficacy of Hypericum
perforatum (HP; ZE117) in the management of smoking cessation, both
as monotherapy and as augmentation to Transdermal NRT for smoking
cessation in a larger sample. Our outcome measure was abstinence
rate (primary outcome variables) determined by CO measurement.
Secondary outcome measures included the number of cigarettes
smoked, cravings and withdrawal symptoms associated with smoking
cessation. Given the similar pharmacological profile to Buproprion,
it was hypothesized that there would be no difference in our primary
outcome variable between the Ze117 or NRT groups. It was also
hypothesized that combined Ze117/NRT would work more effectively
than either NRT or Ze117 used in isolation.

Clinical significance
The results may have significant benefits for influencing health
promotion policies in Australia (and internationally) and may help
encourage current smokers to attempt to quit either for the first time
or after one or more failed attempts. If proven effective the cost of
Ze117 is also highly advantageous in relative terms to other current
treatments. Current treatments are only at best moderately effective.
According to the American Cancer Society (Nov 2013) between 4 and
7% of smokers are able to quit smoking after any attempt and only
about 25% of smokers are able to successfully quit smoking with the
help of current pharmaceutical interventions. Smokers who fail to quit
smoking show significant negative effects on their quality of life, their
health and the community by way of economic burden of caring for
patients with cancer, coronary heart disease and other diseases due
to tobacco smoking. An additional effective treatment will add to our
current treatment measures.

Methods

Ze117 standardized Hypericum perforatum extract

Participants

Ze 117 (Remotiv ) is a HP extract which has been widely tested for
its safety and efficacy and has been clinically proven to be as effective
as, and better tolerated than antidepressants in relieving depressive
symptoms [49-51]. Ze 117 is a standardised product containing 1.375
g HP herb, 500 mcg hypericin and negligible levels of hyperforin [52]
which is the constituent believed responsible for interactions with other

Sixty volunteers, aged between 18 and 60 years, were recruited to
participate in the trial. All interested individuals were screened over the
phone by the research officer to assess their suitability for participation
in the study based on the following selection criteria: Smoking for
at least 5 years and currently smoking at least 10 cigarettes per day,
at least one prior attempt at quitting smoking, motivation to quit
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smoking, weighing more than 45 kg, no history of anxiety/depression,
not currently taking any prescription medications, no other chronic
health conditions , not currently or in past 6 months taking HP or
antidepressants, not currently or in past 6 months classified as being
addicted to any substances apart from nicotine, not currently using
NRT and not pregnant or lactating. Once deemed suitable to participate
in the study participants committed to a quit date with the research
officer and were booked in for their first testing session 4 weeks prior
to their quit date. All testing was conducted at Swinburne University
Hawthorn Campus. All participants provided informed consent to
participate in the study which was approved by Swinburne University
Human Research Ethics committee.

Study design
The study was conducted over a 14 week period at the Brain Sciences
Institute at Swinburne University of Technology, Hawthorn. Following
the first (baseline) visit, participants were randomly allocated to one
of three treatment groups: Group 1-Hypericum perforatum (Ze117;
500 mcg×2 daily), Group 2-Transdermal NRT (Nicabate CQ clear)
and Group 3-Hypericum perforatum (Ze117; 500 mcg×2 daily) and
Transdermal NRT (Nicabate CQ clear).
The primary endpoints were: (1) The mean number of smokers in
each treatment group, as defined by a reading of ≥ 6 ppm on the Benfont
Smokerlyzer at Visit 4, 10 weeks post quitting smoking. (2) Change in
the mean number of cigarettes smoked per week in each treatment
group at Visit 4, 10 weeks post quitting smoking in comparison to
Baseline. The secondary endpoints were state anxiety measured by
the State Trait Anxiety Inventory (STAI), DSM criteria for nicotine
dependence & Fagerstrom dependence measures.

Investigational treatments
Remotiv® Ze117: Ze117 is a high quality standardized HP extract
manufactured by Zeller (Switzerland) which contains 1.375 g HP herb
and 500 mcg hypericin. Ze117 has clinically established safety and
efficacy as an antidepressant [49-51]. As with most antidepressants, it
takes four to six weeks administration of Ze117 to achieve therapeutic
benefits [46]. Therefore, participants taking Ze117 commenced a washin period (500mcg hypericin×2/d) of four weeks (28 days) prior to the
quit date. Ze117 is sold in Australia by Flordis under the registered
trademark Remotiv®.
Nicabate CQ (clear): It is an over the counter pharmaceutical and
treatment consists of a ten week step down process consisting of three
stages: Step 1: Weeks 1-5-Six weeks on a patch delivery of 21 mg nicotine
over 24 hours; Step 2: Weeks 6-7-Two weeks on a patch delivering 14
mg of nicotine over 24 hours; Step 3: Weeks 8-10-Two weeks on a 7 mg
of nicotine delivery over 24 hours.

Materials
Smoking abstinence was confirmed using The Bedfont Compact
Smokerlyser (Bedfont instruments, Kent, UK). The Bedfont
Smokerlyser measures carbon monoxide (CO) levels in the breath in
parts per million (ppm). This measurement is based on the conversion
of CO to CO2 over a catalytically active electrode. When the breath
is held, equilibrium is established between CO in the blood and CO
in alveolar air, therefore there is a high degree of correlation between
breath CO levels and COHb concentration [56]. In the current study, a
measurement of 6 ppm was taken as confirmation of the smoking status
of participants. This is a more stringent cut-off value used by Parsons et
al., [43] who used 10 ppm and Sood et al., [48] who used 8 ppm.
Altern Integ Med
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The Fagerström Test for Nicotine Dependence (FTND) [57] is an
8-item self-report questionnaire, with a total score ≥ 7 indicative of
high nicotine dependence. The State-Trait Anxiety Inventory (STAI)
[58] is a self-report assessment device consisting of two parts: (i) State
Anxiety, a 20-item scale measuring an individual’s transitory feelings
of tension and apprehension, and (ii) Trait Anxiety, a 20-item scale
measuring relatively stable individual differences in anxiety proneness.
In this paper we report the state component of the STAI.

Procedure
Participants were required to attend Swinburne University for an
initial baseline visit 4 weeks prior to quitting cigarettes, then again for
a retest at week 4 (quit date), week 10 (6 weeks post quit) and week 14
(10 weeks post quit).
Visit 1: Baseline visit Pre-quit (Week 0): Participants visited
Swinburne University 4 weeks prior to their quit date for the first
testing session. During this first visit, participants completed a general
questionnaire regarding their health, demographics, vitals (blood
pressure, pulse rate), educational and social economic status, and
smoking habits. During each testing session the following assessments
were administered: the Fagerström Test for Nicotine dependence
(FTND) as a measure of smoking dependence. The State-Trait
Anxiety Inventory (STAI), a self-report assessment device designed to
measure participants’ subjective feelings of tension and apprehension.
Carbon monoxide breath analysis performed using the Bedfont Micro
Smokerlyser to verify participant smoking status, with readings above
6 ppm confirming that the participant is a smoker. DSM IV structured
questionnaire, to measure Nicotine withdrawal symptoms and cravings.
A participant self-report diary was used to monitor adverse events
and the number of cigarettes smoked during the quit period, with
quitting rate expressed as the percentage of participants with confirmed
abstinence. To help increase compliance, participants were asked to
email or post the self-report diary to Swinburne University on a weekly
basis. During the first 4 weeks of the trial (4 weeks pre-quit date)
participants randomized to the HP group were required to start taking
the recommended HP dose, for 28 days prior to the quitting smoking.
Visit 2: Quit date (Week 4). On the quit date all participants were
asked to continue taking these treatments for the remaining treatment
duration period. Participants in the NRT treatment groups (groups
2&3) commenced treatment with 21 mg dose patches for 6 weeks.
Visit 3: 6 weeks post quit date (Week 10): On the third visit
participants in the NRT group ceased taking the 21 mg treatment dose
and commenced the 14 mg patch dosage for 2 weeks, followed by the
final step down process of 7 mg patches per day for the final 2 weeks of
the treatment period. The trial was then continued for a further 4 weeks
with a fourth testing session conducted at week 14 (10 weeks post quit
date) of the trial using the same tests.
Visit 4: 10 weeks post-quit (Week 14). Participants from all three
groups discontinued treatment and visited the BSI for follow up testing.

Statistical analysis
For the primary outcome variables non-parametric tests were used
to assess differences in the number of smokers at week 14 identified
by the Bedfont CO measure. For the secondary measures, repeated
measures parametric analysis of variance was used to examine both
changes from week 4 to week 14 (Time) and differences in changes in
the measures from week to 14 that may differ between the groups (Time
by Treatment).
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Results

Variable

Group

Mean

SD

Mean

SD

Analysis of the number of current smokers as assessed by the
Bedfont Smokerlyzer (6 ppm) was used as the primary outcome
variable. A score of 1 denotes negative test (i.e. non-smoker with a
Bedfont score of less than 6 ppm) and a score of 2 denotes a positive
CO test (i.e. smoker with a Bedfont score of 6 or greater) (Table 1).

Tolerance

Ze117

4.0

3.0

2.8

2.2

NRT

5.1

2.3

1.6

2.8

Ze117/NRT

4.8

2.6

2.4

2.4

Ze117

1.6

.49

1.9

.26

NRT

1.6

.47

1.9

.25

There was no statistical difference between the three groups in the
number of smokers at either the quit date (week 4) or at the completion
of the study (Week 14, 10 post-quit). For the assessment of smoking
status at week 4 all participants were smokers according to the Bedfont
CO values. Using non-parametric statistics to assess differences in the
number of smokers at the end of the treatment date-week 14 (10 weeks
after the quit date) no statistically significant differences between the
groups were found (Kruskal Wallis Independent samples test=.483
df=2, p>.785).

Ze117/NRT

1.8

.39

1.9

.24

Craving

Ze117

4.6

1.1

4.7

1.5

NRT

4.5

0.6

6.3

1.5

Ze117/NRT

3.5

1.1

5.3

1.6

Ze117

16.6

3.1

18.0

3.8

NRT

17.8

3.3

21.5

3.3

Ze117/NRT

17.1

3.4

19.4

4.4

Ze117

14.4

3.5

17.4

5.3

NRT

14.4

3.5

21.5

2.5

Ze117/NRT

12.4

3.5

16.7

5.6

Secondary outcome variables

State Anxiety

Ze117

33.3

7.3

34.9

6.9

NRT

34.7

7.2

32.1

10.6

Ze117/NRT

36.5

9.1

35.1

12.1

Primary Outcome: Smoking status at week 14

We also examined data for the STAI (state anxiety), DSM criteria &
Fagerström dependence measures for both the factors of time (changes
in scores between the quit date and week 14 (completion of the
treatment) as well as time by treatment factor (changes in time between
the three groups). The mean and SDs for these variables are presented
in Table 2.
Fagerström Tolerance was found to be significantly reduced at
10 weeks following the quit date across treatment groups F=22.7,
P<.001, although the treatment×time interaction was found to be
non-significant F=1.8 NS. Fagerström Dependence was found to be
significantly increased at 10 weeks following the quit date F=12.8,
P<.001, with the treatment×time interaction also non-significant F=.72
NS. Fagerström Craving was found to be significantly reduced at 10
weeks following the quit date across treatment groups F=25.9, P<.001,
and the treatment×time interaction was also found to be significant
F=5.5, p<.01. Fagerström Relapse (positive) was found to be significantly
increased at 10 weeks following the quit date F=19.3, P<.001, with the
treatment ×time interaction non-significant F=1.4 NS. Fagerström
Relapse (negative) was found to be significantly increased at 10 weeks
following the quit date F=32.0, P<.001, with the treatment×time
interaction non-significant F=2.3 NS. State Anxiety was now found to
be significantly changed at 10 weeks following the quit date F=.38, NS,
and neither was the treatment×time interaction significant F=.86 NS.

Discussion
The finding of no significant differences between groups in the
numbers of smokers at 10 weeks following the quit date indicates that
each treatment condition was equally effective in smoking cessation as
measured by CO criteria of 6 ppm. Interestingly there is a small trend
that is suggestive of the combined treatment condition working best
but this would only reach statistical significance in a much larger trial.
Visit 2 Quit date

Visit 4 10 weeks post quit

(SDs)

(SDs)

Ze117 group

1.27 (.46)

1.60 (.50)

Nicotine patches (NRT)
group

1.18 (.39)

1.60 (.51)

Ze117/NRT group

1.00 (.00)

1.52 (.51)

Table 1: Mean number of participants classified as smokers at quite date and 10
weeks after treatment based on CO value of 6ppm (1=non-smoker-less than 6
ppm; 2=smoker 6 ppm or greater).
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Dependence

Relapse-Positive

Relapse-Negative

Week 4
(quit date)

Week 14
(10 weeks post quit)

Table 2: Means, SDs for secondary outcome variables at week 4 (quite date) and
week 14 (10 weeks of treatment).

Additionally future research should also use urinary measures to assess
abstinence. Compared to urinary cotinine, CO has a shorter half-life and
therefore the rate of false negative classifications using CO measurements
may be higher. This will have implications for participation rates as well
as costs in future studies but urinary measures provide the strongest
evidence of abstinence. Nevertheless, CO measurements have been
used previously in all of the HP smoking cessation studies and provide
an efficient and consistent measure in which to interpret the findings of
the current study within the background of previous studies.
Given the equivalence of our primary measure between treatment
groups, an analysis of the secondary measures was helpful in revealing
potential differences between treatments in the context of smoking
cessation.There was a significant time interaction for all variables
except state anxiety. This suggests that across all three interventions
(HP, NRT and combined HP/NRT) there were significant changes in
our secondary measures except for state anxiety. These changes were
in the expected direction based on previous studies indicating that
feelings of dependence generally increased and tolerance decreased
over the course of the intervention. In terms of the differential effects
of the treatments, there were no significant differences in the time by
treatment effects for all of our secondary variables except for craving.
For this variable the HP treatment was best at reducing feelings of
craving and this is consistent with the known pharmacological action of
HP as well as previous research which has shown reductions in craving
after HP administration [42]. Reducing craving may be an important
factor in smoking cessation for many smokers and this mechanism
may help explain the equivalence in cessation across the three different
treatments arms observed in the present study. Clearly there are other
mechanisms independent of craving that can be attributable to the
efficacy of NRT observed in the current study.
There were some important components to the present trial. First,
this was the first trial to examine this particular HP extract (Ze117)
on smoking cessation. Ze117 is a high quality well-researched HP
extract that has proven consistency, potency and quality. Another
important component to this trial was that it included for the first
time a combined HP/NRT arm. Given the different pharmacological
actions of HP and NRT it could have been reasonably expected that the
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combination treatment would show greater effect in terms of smoking
cessation than either intervention alone. This was not the case. In fact
the only significantly different effect observed in the current study was
the significant decrease in symptoms of craving observed in the Ze117
treatment arm.
The purpose of this study was to examine whether there was
preliminary evidence for Ze117 rather than HP in general as a treatment
option for smoking cessation. To adequately examine the efficacy
of HP as a treatment option for smoking cessation a study in which
several different HP extracts would need to be compared for smoking
cessation. Therefore the results of this study can only generalise in terms
of the specific HP extract used in the current study. As such there is
now preliminary evidence justifying a considerably larger randomized
double blind study administering this particular HP extract (Ze117) for
smoking cessation. Data from this large study if confirming the pilot
data could lead to the use of Ze117 for smoking cessation in addition
to NRT.
The smoking cessation market is currently a multi-billion dollar
industry and many smokers fail to give up smoking after NRT treatment.
Additionally NRT and other treatments show a considerably higher
side-effect profile than HP in general and Ze117 specifically. Increasing
choice of treatments may have important consequences for reducing
the burden of smoking related diseases in many countries. Future
studies should also employ more mechanistic measures and examine
interactions between nicotine and Ze117 for cytochrome enzymes (i.e.
safety data). Given the significant health effects of smoking, alternative
treatments for smoking cessation are urgently required. The results of
this study, although preliminary provide a strong framework for larger
efficacy and safety studies.
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